Sichuan Kelun-Biotech Biopharmaceutical (6990 HK): Synthetic Expert Call Transcript (08 Jul 2026)
Yesterday’s HK$2.72 billion (US$350 million) share placement was strategically timed to capitalize on the high market valuation following major...
98 Views
Aequitas: Kelun-Biotech Placement - Steady Performance; Valuation May Temper Appeal
Sichuan Kelun-Biotech Biopharmaceutical Co is looking to raise up to US$350m from a primary placement. In this note, we will talk about the...
120 Views
Hong Kong 2025 Placements - Year so Far and Trends for Potential Primary Placements
1H25 saw a sharp turnaround in HK placements, with 36 US$100m+ deals so far. This compares to only 14 in 2022, 13 in 2023, and 15 in 2024. In this...
893 Views
China Healthcare Weekly(July20)-WuXi AppTec 25H1, Sino Biopharm Acquire LaNova, United Lab Placement
WuXi AppTec’s 25H1 Profit Alert indicates 2025 result may beat expectation. Sino Biopharm's acquisition of LaNova show high cost...
961 Views
Sichuan Kelun-Biotech Biopharm (6990.HK) - Current High Valuation Is Not Secure
The market has high hopes for SKB264's clinical data on NSCLC/TNBC, which will impact Akeso's future expectations. Be cautious of share price...
567 Views